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Abstract
Background: The occurrence of nosocomial pneumonia (NP) in the hospital setting is especially problematic, as it
is associated with a greater risk of in-hospital death, longer stays on mechanical ventilation and in the intensive
care unit (ICU), more need for tracheostomy, and significantly higher medical care costs.
Methods: Review of the pertinent English-language literature.
Results: The adverse effect of NP on healthcare outcomes has increased pressure on clinicians and hospital
systems to prevent this infection. This brief review provides an overview of the current approaches to the
prevention of NP, focusing primarily on ventilator-associated pneumonia (VAP).
Conclusion: Clinicians working in ICUs should consider the following recommendations: (1) Develop a VAP
prevention bundle based on evidence-based guidelines; (2) monitor the rates of VAP prior to and during
implementation of the program; (3) make adjustments according to VAP occurrence; and (4) integrate VAP
prevention with other quality improvement programs.
Pneumonia associated with the need for mechanicalventilation in the intensive care unit (ICU) setting is one of
the most common infections managed by intensivists. The
current classification of pneumonia in the ICU includes
community-acquired pneumonia (CAP), hospital-acquired
pneumonia (HAP), ventilator-associated pneumonia (VAP),
and nursing home-associated pneumonia (NHAP) (Table
1)[1–3]. Health care-associated pneumonia (HCAP) is the
newest category of pneumonia and in many developed
countries probably is the most common type necessitating
ICU care. This is a distinct type of nosocomial pneumonia
(NP), the others being HAP and VAP, that is present at the
time of hospital or ICU admission where patients have spe-
cific underlying risk factors, including residence in a nursing
home or long-term care facility; recent hospitalization or
treatment with antibiotics; receipt of home or hospital-based
intravenous therapy, wound care, or dialysis; and immuno-
suppression [2,3].
Patients with HCAP are more similar to patients with HAP
and VAP and differ from patients with CAP because of the
common presence of infection with multi-drug resistant
(MDR) bacteria and the greater likelihood of co-morbidities,
including cancer, chronic kidney disease, heart disease,
chronic obstructive lung disease, immunosuppression, de-
mentia, and impaired mobility [4–8]. From a prevention
standpoint, HAP and VAP are most amenable to useful
strategies applied in the hospital setting. However, the pre-
vention of pneumonias developing outside of the hospital
(CAP, HCAP) also can be accomplished, to some extent,
through the use of specific hospital-based strategies [9,10].
The medical literature and available clinical evidence cur-
rently is most robust for VAP and less developed for HAP and
HCAP. Therefore, this review focuses on the prevention of
VAP, and the reader should assume that the recommenda-
tions also apply to HAP and HCAP unless stated otherwise.
However, it is important to recognize that not all VAP pre-
vention studies are similar in the rigor with which infection
was defined. That is, some studies used microbiologic criteria
to confirm infection, whereas others employed less-specific
clinical criteria. Readers should take this into account when
considering including specific interventions in their preven-
tion bundles, especially costly interventions or those carrying
a risk to the patient or environment.
Pathogenesis of Nosocomial Pneumonia
Under basal conditions, the lower respiratory tract is
sterile. Thus, for pneumonia to develop, bacteria must be in-
troduced into the lungs, typically by being aspirated from
either the upper respiratory tract or the gastrointestinal tract.
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Introduction generally is associated with impairment of host
defenses, both locally and systemically. The pathogenesis of
VAP thus is a dual process requiring colonization of the
aerodigestive tract with potentially causative pathogens fol-
lowed by aspiration of secretions contaminated with these
pathogens that overcome lower respiratory tract defense
mechanisms, resulting in infection.
A leading hypothesis regarding the pathogenesis of VAP,
and NP in general, is that the oropharynx is overgrown by
microorganisms, which subsequently are aspirated into the
lungs and colonize the airway. This hypothesis is supported
by the observation that whereas enteric gram-negative bac-
teria are absent from the oropharynx under basal conditions,
they can be detected in that site in nearly 75% of critically
ill patients [11]. A comparison of bacterial DNA samples
on the tongues of critically ill patients with organisms re-
covered from bronchoalveolar lavage (BAL) samples sup-
ports this theory [12]. Upper airway colonization by enteric
bacteria occurs in 45% to 100% of intubated patients. Besides
being colonized by aspirated endogenous flora, the airways
may be colonized by exogenous flora as a result of cross-
contamination from other ICU patients through inadvertent
transmission by healthcare workers.
A complementary hypothesis is that the upper gastrointes-
tinal tract plays a critical role in the pathogenesis of VAP. Ac-
cording to this view, the stomach is a primary site of
colonization that may subsequently infect the lung through
bacterial overgrowth and retrograde movement, followed by
aspiration of organisms from the oropharynx. The small de-
crease in the mortality rate seen in certain ICU patient popula-
tions after selectivedecontamination of the digestive tract (SDD)
supports the idea that gut flora play a role in the pathogenesis of
VAP and possibly HAP and HCAP. Chronic infection of bio-
films on an endotracheal tube also may play a role [13].
Prevention of Nosocomial Pneumonia
Pharmacologic approaches (Table 2)
Topical iseganan. Iseganan is an antimicrobial peptide
with activity against gram-positive and gram-negative bac-
teria and yeast. In a multicenter randomized trial, topical
oropharyngeal administration of iseganan was not associated
with a reduction in VAP [14].
Orodigestive decontamination. Orodigestive decontami-
nation (ODD) is the use of a prophylactic antimicrobial
Table 1. Pneumonia Classification for Patients in the Intensive Care Setting
CAP Infection present at hospital admission in patients who do not meet the criteria for HCAP
HCAP Pneumonia present at hospital or ICU admission in patients with at least one of the following risk factors:
– Hospitalization for 2 days in an acute-care facility within 180 days of infection
– Residence in a nursing home or long-term care facility
– Antibiotic therapy, chemotherapy, or wound care within 30 days of current infection
– Hemodialysis at a hospital or clinic
– Home infusion therapy or home wound care
– Family member with infection caused by MDR bacteria
– Significant immunosuppression (corticosteroids, HIV, organ transplant)
NHAP Pneumonia occurring during residence in a nursing home or rehabilitation facility
HAP Pneumonia occurring typically 48 h after hospital admission in a non-intubated patient
VAP Pneumonia occurring typically 48 h after hospital admission and endotracheal intubation
CAP¼ community-acquired pneumonia; HCAP¼healthcare-associated pneumonia; HIV¼human immunodeficiency virus; MDR¼
multi-drug resistant; NHAP¼nursing home-associated pneumonia; HAP¼hospital-acquired pneumonia; VAP¼ventilator-associated
pneumonia; ICU¼ intensive care unit.
Table 2. Pharmacologic-Based Strategies for Prevention of Ventilator-Associated Pneumonia
Strategy Recommendation Evidence levela References
Topical iseganan No 1 14
Orodigestive decontamination No# 1 15,16
(topical/topical plus intravenous antibiotics)
Oral chlorhexidine Yes 1 19–22
Aerosolized antibiotics No recommendationb 1 23,24
Intravenous antibiotics No recommendationb 1 25
Specific stress ulcer prophylaxis regimen No 1 27
Short-course antibiotic therapy Yes 1 30–32
(when clinically applicable)
Routine antibiotic cycling/rotation/heterogeneityc No 2 33–35
Restricted (conservative) blood transfusion Yes 2 36–38
Vaccines (influenza, pneumococcal)d Yes 1 40,41
a1¼ Supported by randomized trials; 2¼ supported by prospective or retrospective cohort studies; 3¼ supported by case series.
bRoutine use of intravenous, topical, or aerosolized antibiotics for prophylaxis cannot be recommended because of the emergence of
antibiotic resistance [see references 17 and 18] and insufficient data on aerosolized and intravenous antibiotics used alone.
cMay be useful in specific clinical circumstances (as an adjunct to controlling an outbreak of a multi-drug resistant bacterial infection).
dGeneral recommendation without specific evidence for ventilator-associated pneumonia.
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regimen that includes nonabsorbable antibiotics applied
to the oropharynx and gastrointestinal tract along with a
short course of intravenous antibiotics. The technique has
been studied for more than 25 years, and more than 10 meta-
analyses have been written [15]. Despite a fairly consistent
demonstration of modest decreases in the mortality rate and
in blood stream infections, ODD is not in widespread use,
primarily because of concerns about promoting antimicrobial
resistance and uncertain cost-effectiveness. A randomized
trial in more than 6,000 patients was published recently
comparing ODD, oral decontamination with topical agents
alone, and standard care [16]. Compared with standard care,
ODD led to a 28-day mortality rate decrease from 27.5% to
26.9%. The 28-day mortality rate in the oral decontamination
group was similar to that in the ODD group at 26.6%. Because
antimicrobial resistance may take time to develop, however,
its emergence may not be noticed during clinical trials, and
this remains a major concern with the widespread im-
plementation of ODD. Indeed, a followup of this study
showed that increasing bacterial resistance emerged in the
ICUs employing ODD [17,18]. Therefore, the routine use of
ODD for the prevention of VAP cannot be recommended.
Oral chlorhexidine. Like the use of ODD, oral chlorhex-
idine administration has been associated with reductions in
nosocomial infections, including VAP, primarily in patients
undergoing cardiac surgery [19,20]. The overall magnitude of
the effect on the prevention of VAP seems to be modest and
probably is dependent on both the frequency of its adminis-
tration and the concentration of chlorhexidine, as demon-
strated in non-cardiac surgery populations [21,22].
Aerosolized antibiotics. The most recent American Thor-
acic Society/American Infectious Diseases Association
guidelines for the management of NP concluded that aero-
solized antibiotics have not been proved to have value in VAP
treatment but can be considered as an adjunct for VAP caused
by MDR pathogens that are not responsive to standard ther-
apy [3]. Several small studies have been published in support
of the use of inhaled antibiotics for both VAP and tracheo-
bronchitis [23,24]. Although these trials are promising, cur-
rent data are lacking to support the use of inhaled antibiotics
as more than an adjunctive therapy in non-improving pa-
tients. There is no current role for aerosolized antibiotics for
the prevention of VAP.
Intravenous antibiotics. Long courses of intravenous an-
tibiotics can be associated with the emergence of antibiotic
resistance, and therefore, their use should be limited to
treatment indications. One study of cefuroxime administra-
tion for 24 h at the time of intubation in patients with closed
head injury produced a significant reduction in early-onset
VAP [25].
Specific stress ulcer prophylaxis. Stress ulcer prophy-
laxis (antacids, histamine type-2 receptor antagonists, proton-
pump inhibitors) neutralizes gastric acid or reduces gastric
acid secretion, facilitating gastric colonization with poten-
tially pathogenic bacteria and yeast, which can be aspirated
into the lungs and cause lower respiratory tract infections.
Significant debate has ensued regarding the role of stress ulcer
prophylaxis as a promoter of VAP [26]. Nevertheless, no
convincing evidence exists to recommend one agent over
another when stress ulcer prophylaxis is deemed necessary
[27]. More recently, the use of proton-pump inhibitors has
been associated also with the development of CAP, further
linking alterations in upper gastrointestinal colonization to
the development of pneumonia [28,29].
Short-course antibiotic therapy. Available evidence sug-
gests that shorter courses of antibiotic therapy for VAP are
clinically effective and associated with less emergence of an-
tibiotic resistance [28–30].When clinically acceptable, a seven-
to eight-day course of antibiotic therapy should be considered
adequate for patients demonstrating a clinical response to
treatment (resolution of fever, reduced white blood cell count,
improved oxygenation, and decreased respiratory secretions).
Although this may not be a primary mode for the prevention
of VAP, it can result in less emergence of antibiotic-resistant
VAP [28].
Routine antibiotic cycling/rotation. In view of the avail-
able evidence, the routine use of antibiotic cycling or rotation
cannot be recommended for the prevention of VAP [31–33].
Restricted use of blood transfusion. Transfusion of red
blood cells has been associated with the development of
nosocomial infections, including VAP [36–38]. Restricted use
of transfusion therefore seems appropriate to minimize this
risk [39].
Vaccines. Appropriate use of influenza and pneumo-
coccal vaccines is recommended to reduce the incidence of
respiratory failure related to these infections, which could
secondarily increase the occurrence of VAP [40,41]. Clinicians
should follow national recommendations regarding vaccina-
tion policies and chemoprophylaxis in order to minimize the
impact of respiratory illness outbreaks in the community [42].
Non-Pharmacologic Approaches to Preventing
Nosocomial Pneumonia (Table 3)
Use of non-invasive mask ventilation
The endotracheal tube plays an important role in the
pathogenesis of VAP, which has led some authors to rename
this nosocomial infection ‘‘endotracheal-tube associated
pneumonia’’ [43]. Avoidance of endotracheal intubation by
using mask ventilation reduces the occurrence of VAP and
nosocomial sinusitis [44–46].
Avoid re-intubation
Re-intubation is associated with a higher risk of VAP by
facilitating aspiration [47]. Appropriate interventions and
surveillance should be in place to minimize unplanned ex-
tubations resulting in the need for re-intubation. Clinicians
must balance the occurrence of re-intubations as part of the
planned ventilator weaning process with the aim of mini-
mizing the duration of mechanical ventilation, which also can
help to prevent VAP.
Avoid patient transport
Unnecessary patient transport out of the ICU should be
avoided, as such travel has been associated with VAP [48].
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Orotracheal and orogastric intubation
Orotracheal and orogastric intubation have been associated
with reduced incidences of VAP and nosocomial sinusitis
[49,50]. Therefore, the oral route is preferred when intubation
of the trachea and esophagus is necessary in a critically ill
patient.
Early tracheostomy
One trial suggested that early tracheostomy could prevent
VAP [51]. However, a more recent rigorously conducted
study found no benefit [52].
Routine ventilator circuit changes
Manipulation and changing of ventilator circuits may
promote aspiration and increase the occurrence of VAP
[53,54] Therefore, ventilator circuit changes should be made
only when the circuit is damaged or visibly soiled. When
significant condensate accumulates in a circuit, it should be
removed to avoid aspiration and VAP [55].
Routine use of heat-moisture exchangers
Use of heat-moisture exchangers (HMEs) for humidifica-
tion does not reduce the occurrence of VAP consistently
compared with water humidification methods [56–58].
Therefore, deciding on their use is left to the treating physi-
cians. Prolonged use of HMEs has not been associated with a
higher risk of VAP [59,60].
Closed versus open endotracheal suctioning
According to clinical studies, closed and open endotracheal
suctioning systems are linked to similar rates of VAP [61,62].
However, closed systems create less aerosolization of poten-
tially infected airway secretions. Available evidence suggests
that closed suctioning systems need to be changed only when
malfunctioning or visibly soiled [63].
Subglottic suction drainage
Aspiration of subglottic secretions with a specially de-
signed endotracheal tube has been associated with reductions
in VAP [64–67]. However, subglottic suctioning can cause
mucosal injury of the trachea and failure to aspirate secretions
secondary to either increased viscosity or mucosal blockage of
the suction port [68,69].
Shortening the duration of mechanical ventilation
The likelihood of VAP has been linked to the duration of
mechanical ventilation [70]. Therefore, efforts to reduce the
duration of mechanical ventilation by optimizing weaning
attempts and utilizing sedation should be routine [71,72].
Adequate intensive care unit staffing
Inadequate staffing of ICUs has been associated with ex-
cess development of nosocomial infections and prolonged
durations of mechanical ventilation [73,74]. Therefore, ade-
quate staffing should be in place to ensure that protocols
are followed to prevent VAP and other nosocomial infec-
tions, as well as to minimize patient exposure to mechanical
ventilation.
Silver-coated endotracheal tube
Biofilm formation is an important pathogenic element in
the development of VAP (75). Recent clinical investigations
suggest that a silver-coated endotracheal tube is safe and can
reduce the incidence of VAP by almost 50% during the first
ten days of mechanical ventilation [76,77]. Additionally, a
retrospective analysis of the NASCENT study suggests that
use of a silver-coated endotracheal tube may be associated
with better outcomes for patients developing VAP [78].
Polyurethane cuffed endotracheal tubes
Endotracheal tube cuffs made of ultrathin polyurethane
rather than polyvinyl chloride theoretically reduce channel
Table 3. Non-Pharmacologic-Based Strategies for Prevention of Ventilator-Associated Pneumonia
Strategy Recommendation Evidence levela References
Use of non-invasive mask ventilation Yes 1 43–46
Avoid re-intubation Yes 2 47
Avoid patient transports Yes 2 48
Orotracheal intubation preferred Yes 1 49
Orogastric intubation preferred Yes 2 50
Early tracheostomy No 1 51,52
Routine ventilator circuit changes No 1 53,54
Use of heat-moisture exchanger Yes 1 56–58
Closed endotracheal suctioning Yes 1 61–63
Subglottic secretion drainage Yes 1 64–67
Shortening the duration of mechanical-ventilation Yes 1 71,72
Adequate intensive care unit staffing Yes 2 73,74
Silver-coated endotracheal tube Yes 1 76,77
Polyurethane endotracheal tube cuff Yes 1 79,80
Semi-erect positioning Yes 1 81,82
Rotational beds Yes 1 83–85
Chest physiotherapy No 1 86–88
Use of protocols/bundles Yes 2 89–91
a1¼ Supported by randomized trials; 2¼ supported by prospective or retrospective cohort studies; 3¼ supported by case series.
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formation and minimize the volume of secretions micro-
aspirated around the cuff. Limited data from some popula-
tions have demonstrated their efficacy [79,80]. Various shapes
of the ultrathin polyurethrane cuffs have been employed in
the commercially available endotracheal tubes (cylindrical,
tapering funnel-like design). Unfortunately, head-to-head
studies of the efficacy of various cuff designs for the preven-
tion of aspiration and VAP are not available. The develop-
ment of endotracheal tubes that combine multiple prevention
features (ultrathin polyurethane cuff with subglottic suction-
ing) may allow even greater reductions in VAP occurrence,
although this has yet to be confirmed in clinical trials.
Semierect positioning
Supine positioning facilitates aspiration in the intubated
patient and should be avoided if possible [81]. However,
achieving head elevation to 458 may be difficult in many
clinical situations. Under those circumstances, the head of the
bed should be raised to the highest level applicable [82].
Rotational beds
Several small trials have shown that rotating beds can re-
duce the occurrence of VAP [83–85]. However, because of the
cost of these beds and the populations studied, their use
should be based on perceived benefit and available resources
in particular cases.
Chest physiotherapy
In view of the available evidence, the routine use of chest
physiotherapy cannot be recommended for the prevention of
VAP [86–88].
Protocols/bundles to Prevent Ventilator-Associated
Pneumonia
An increasing body of evidence suggests that the routine
use of bundles or protocols aimed at preventing VAP can be
successful [89–91]. The challenge is to ensure that compliance
with the elements of the bundles and protocols is adhered to
over time in order to sustain the early benefits. Additionally,
clinicians must evaluate new technologies for inclusion in
their established bundles. One example is the routine use of
chlorhexidine baths for enhanced environmental control in
order to reduce the occurrence of nosocomial infections. The
data on the use of these baths to prevent VAP are mixed
[92,93]; however, the overall reduction in ICU-acquired in-
fections resulting from their use can justify the inclusion of
such baths in a VAP prevention bundle.
Prevention Protocols
An education-based program at Barnes-Jewish Hospital
directed toward respiratory care practitioners and ICU nurses
was developed by a multidisciplinary task force to highlight
correct practices for the prevention of VAP [90]. Each partic-
ipant was required to take a test before reviewing a study
module and an identical test after completion of the module.
Following implementation of the module, the rate of VAP
decreased to 5.7/1,000 ventilator days from 12.6/1,000 ven-
tilator days [90]. The estimated cost savings secondary to the
lower rate of VAP for the 12mos following the intervention
was estimated to exceed $400,000. This educational protocol
was then implemented across the four largest hospitals in the
local healthcare system [89]. The VAP rates for all four hos-
pitals combined dropped by 46%, from 8.75/1,000 ventilator
days in the year prior to the intervention to 4.74/1,000 venti-
lator days in the 18mos following the intervention (p< 0.001).
Statistically significant decreases in rates were observed at the
pediatric hospital and at two of the three adult hospitals. No
change in VAP rates was seen at the community hospital with
the lowest rate of studymodule completion among respiratory
therapists (56%). In addition to showing the effectiveness of a
protocol for VAP prevention, these studies highlight the im-
portance of compliance with the elements of the protocol to
ensure its success. This same protocol also has been successful
in the ICUs of a hospital in Thailand [91].
Lansford et al. developed a simple protocol for the pre-
vention of VAP in trauma patients focusing on head-of-bed
elevation, oral cleansing with chlorhexidine, a once-daily re-
spiratory therapist-driven weaning attempt, and conversion
of nasogastric to orogastric feeding tubes [50]. Implementa-
tion of the protocol was associated with a significant reduc-
tion in the rate of VAP (11 occurrences in 1,600 days of
ventilator support [6.9/1,000 ventilator days] vs. two occur-
rences in 703 days of ventilation [2.8/1,000 ventilator days]).
Elements of this protocol have proved effective in other
surgical/trauma units as well [94]. However, compliance
with infection control protocols often wanes over time and
can be influenced significantly by staffing levels in the ICU
[95,96]. Wahl et al. have shown that a computerized flow
sheet employed in the ICU could improve compliance with
care measures involved in the prevention of VAP, as well as
other protocols [97].
Most recently, Bouadma et al. illustrated the benefits of a
bundled approach to the prevention of VAP [98]. Their pro-
gramwas implemented in a 20-bed medical ICU of a teaching
hospital in France and involved all healthcare workers. The
French intervention included a multidisciplinary task force,
an educational session, direct observations with perfor-
mance feedback, technical improvements, and scheduled re-
minders. It focused on eight targeted measures based on well-
recognized published guidelines, easily and precisely defined
acts, and the bedside behavior of directly concerned health-
care workers. Compliance assessment consisted of five four-
week periods (before the intervention and one, six, 12, and
24mos thereafter). Hand hygiene and glove-and-gown use
compliances were high (68% and 80%) initially and remained
stable over time. Compliance with all other preventive
measures was low initially but increased steadily over the
two-year period of the study: backrest elevation (5–58%) and
tracheal cuff pressure maintenance (40–89%), which im-
proved after simple technical equipment implementation;
orogastric tube use (52–96%); gastric overdistention avoid-
ance (20–68%); good oral hygiene (47–90%); and elimina-
tion of nonessential tracheal suctioning (41–92%). The VAP
prevalence rate decreased by 51% after implementation of
the intervention (p< 0.001). This long-lasting program for
preventing VAP increased compliance with preventive mea-
sures that are directly dependent on healthcare workers’
bedside performance. The use of a multidimensional frame-
work appeared to be critical for the success of this program, as
has been demonstrated for similar bundled approaches to
VAP prevention [89,90].
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Protocols, standardized order sets, checklists, and clinical
practice teams all provide approaches for the prevention of
VAP, as well as for the overall enhancement of critical care.
Depending on local expertise and resources, an approach
to quality care improvement in the ICU should be im-
plemented and monitored over time (Table 4). The SMART
approach for the prevention of nosocomial infections seems to
be a concise framework for developing and implementing
successful programs using available prevention strategies
[99]. Evidence-based recommendations are available that re-
duce nosocomial ICU infection rates[100–102], especially
when simple tactics are bundled. To increase the likelihood of
success, the SMART approach, in which specific objectives or
outcomes that are precisely defined and quantified (e.g., 25%
reduction of VAP with protocol implementation), should be
implemented. The outcome must be measureable, achievable,
and, most important, clinically relevant. This will facilitate
buy-in from stakeholders such as staff who have to carry out
the protocols and bundles. Appointing a team to champion
the intervention and collaboration with hospital administra-
tors will help ensure the success of the interventions. Finally,
the intervention must be time bound so that success or failure
can be assessed objectively [98].
Summary Recommendations and Conclusion
Optimal management and prevention of nosocomial in-
fections in the ICU setting is an important element of care for
the critically ill patient. Clinicians need to develop systems
within ICUs aimed at optimizing the care of patients in order
to improve their clinical outcomes. In the future, emerging
advances in the design of endotracheal tubes [103], use of
probiotics [104], and development of new antibiotics should
further our ability to prevent and treat NP. In the meantime,
clinicians working in ICUs should consider the following
recommendations:
1. Develop a VAP prevention bundle using evidence-
based guidelines and the input of local experts in in-
fection control and critical care;
2. Monitor the rates of VAP prior to and during the im-
plementation of the prevention program to determine
its success or failure;
3. Make adjustments to the prevention program according
to VAP occurrence in terms of the bundle elements,
strategies to enhance bundle compliance, and changes
in patient mix, target pathogens, or changing defini-
tions of VAP (e.g., U.S. Centers for Disease Control and
Prevention Conference for Establishing a VAP Surveil-
lance Definition, scheduled for Fall 2010);
4. Integrate VAP prevention with other quality improve-
ment programs in the ICU to minimize redundancies
and optimize the use of resources.
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